Patents Examined by Amanda L Aguirre
  • Patent number: 11905244
    Abstract: Methods of identification of inhibitors of calcium release-activated calcium (CRAC) channel and small molecule inhibitors of CRAC channel, including methods of their synthesis and pharmaceutical use, are disclosed.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: February 20, 2024
    Assignee: The Texas A&M University System
    Inventors: Yubin Zhou, Lian He
  • Patent number: 11905255
    Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
    Type: Grant
    Filed: July 28, 2023
    Date of Patent: February 20, 2024
    Assignee: PFIZER INC.
    Inventors: Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
  • Patent number: 11891384
    Abstract: The present invention relates to the novel key intermediate, 4-{4-[(SS)-(Aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]-phenyl}-morpholin-3-one perchlorate, m the synthesis of rivaroxaban. The invention further relates to the crystalline form of novel intermediate, the process to prepare the novel intermediate and method of preparing rivaroxaban using this novel intermediate. The invention provides an improved and efficient process for preparation of Rivaroxaban.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: February 6, 2024
    Assignee: Unichem Laboratories Ltd
    Inventors: Dhananjay G. Sathe, Arijit Das, Sanjay Raikar, Yashwant S. Surve, Bhushan S. Pandit
  • Patent number: 11884634
    Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
    Type: Grant
    Filed: November 21, 2022
    Date of Patent: January 30, 2024
    Assignee: PFIZER INC.
    Inventors: Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
  • Patent number: 11884642
    Abstract: The present invention discloses novel compounds which are useful as potassium channel openers, in particular as openers of the Kv7.4 potassium channel. The novel compounds are compounds according to formula I, wherein n=0 or 1, RL is a substituent selected from the group consisting of unsubstituted or substituted cycloalkyl groups, in particular bicycloalkyl groups, unsubstituted or substituted phenyl groups, unsubstituted or substituted thienyl groups or cyclopentathienyl groups, and unsubstituted or substituted indanyl groups, which optionally contain heteroatoms, and RR is a substituent selected from the group consisting of unsubstituted or substituted phenyl groups or unsubstituted or substituted benzyl groups, which optionally contain heteroatoms, or a stereoisomer, a tautomer, a prodrug or a salt, preferably pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: January 30, 2024
    Assignee: Acousia Therapeutics GmbH
    Inventor: Michael Boes
  • Patent number: 11884635
    Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
    Type: Grant
    Filed: July 28, 2023
    Date of Patent: January 30, 2024
    Assignee: PFIZER INC.
    Inventors: Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
  • Patent number: 11865104
    Abstract: A method of treating cancer is described. The method includes administering a therapeutically effective amount of a TET2 activating compound or pharmaceutically acceptable salt thereof to a subject in need of treatment. The TET2 activating compounds are ?-ketoglutarate derivatives. A method of treating or preventing cancer in a subject that includes the step of analyzing a biological sample to determine if cells of the biological sample exhibit a TET2 mutation in addition to administering a TET2 activator is also described.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: January 9, 2024
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Jaroslaw Maciejewski, Babal K. Jha, James G. Phillips, Thomas Radivoyevitch, Yihong Guan, Anand D. Tiwari
  • Patent number: 11857551
    Abstract: Acquired hearing loss due to chemotherapy or noise exposure is a major health problem, and cisplatin chemotherapy often causes permanent hearing loss in cancer patients. However, there are no FDA-approved drugs for the treatment or prevention of cisplatin- or noise-induced hearing loss. In one aspect, use of compounds as an active agent to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: January 2, 2024
    Assignee: Ting Therapeutics LLC
    Inventors: Jian Zuo, Pezhman Salehi Dermanaki
  • Patent number: 11857550
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: January 2, 2024
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States Government as Represented By the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Patent number: 11845732
    Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
    Type: Grant
    Filed: February 17, 2023
    Date of Patent: December 19, 2023
    Assignee: PFIZER INC.
    Inventors: Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
  • Patent number: 11839214
    Abstract: The present invention relates to fungicidal mixtures comprising at least one substituted pyridines (compounds I) and at least one active compound II in a weight ratio of from 100:1 to 1:100; to a method for controlling phytopathogenic harmful fungi using mixtures of at least one compound I and at least one compound II in a weight ratio of from 100:1 to 1:100; to the use of mixtures comprising compounds I and compounds II for controlling phytopathogenic harmful fungi; to agrochemical compositions comprising these mixtures; and to agrochemical compositions further comprising seed.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: December 12, 2023
    Assignee: BASF SE
    Inventors: Nadine Riediger, Bernd Mueller, Ana Escribano Cuesta, Michael Seet, Waldemar Bernat, Lutz Brahm
  • Patent number: 11820750
    Abstract: The present disclosure generally relates to the field of biological control of Ectropis. oblique and Ectropis grisescens as pests in tea plantations, and in particular to a high efficient sex pheromone lures for E. oblique and E. grisescens. By combinating (3Z,6Z,9Z)-octadecatriene with two different configurations of (3Z,9Z)-6,7-epoxy-octadecadiene and (3Z,6Z)-9,10-epoxy-octadecadiene, high efficient sex pheromone lures were obtained. The high efficient sex pheromone lures have significantly improved trapping effect on E. oblique and E. grisescens.
    Type: Grant
    Filed: February 22, 2023
    Date of Patent: November 21, 2023
    Assignee: CHANGZHOU UNIVERSITY
    Inventors: Xin Chen, Ke Chen, Xueyuan Zhang, Chengfang Zhang, Jianlong Bi, Yanqiang Jin, Mingwei Shan, Shuai Zhao, Mingcheng Qian
  • Patent number: 11820748
    Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
    Type: Grant
    Filed: January 27, 2023
    Date of Patent: November 21, 2023
    Assignee: PFIZER INC.
    Inventors: Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
  • Patent number: 11785842
    Abstract: An N heterocyclic planar photocoupler output material is provided, and includes a structural formula as follows: R1—R2—R1. The N heterocyclic planar photocoupler output material is selected from any one of following formula structures: The photocoupler output material has a very high “n” value, so that the top-emitting electroluminescent devices using it have achieved very high luminous efficiency. Therefore, it saves time and costs. Also, a method of preparing an N heterocyclic planar photocoupler output material is provided.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: October 10, 2023
    Assignee: Wuhan China Star Optoelectronics Semiconductor Display Technology Co., Ltd.
    Inventor: Jiajia Luo
  • Patent number: 11779018
    Abstract: The present invention provides a compound that has an excellent control effect on arthropod pests, and is represented by formula (I) [wherein Q represents a group represented by Q1, or the like, n is 0, 1, or 2, R2 represents a C1-C6 alkyl group which may optionally have one or more halogen atoms, or the like, Ya represents an oxygen atom, a sulfur atom, or NR3a, G1 represents a nitrogen atom or CR5a, G2 represents a nitrogen atom or CR5b, A2 represents a nitrogen atom or CR4a, A3 represents a nitrogen atom or CR4b, A4 represents a nitrogen atom or CR4c, and R3a, R4a, R4b, R4c, R5a, and R5b represent a C1-C6 chain hydrocarbon group or the like, and T represents a C1-C10 chain hydrocarbon group which may optionally have one or more halogen atoms, or the like].
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: October 10, 2023
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Ryota Maehata, Kohei Orimoto, Takamasa Tanabe, Yasumasa Saito
  • Patent number: 11771677
    Abstract: Defined herein are immunomodulating Formula (1) compounds wherein R, R0, R1, R2, R3 and W are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The invention also includes methods for treating an inflammatory and/or immunological disease or disorder in an animal by administering a therapeutically effective amount of a Formula (1) compound, stereoisomer thereof, and a pharmaceutically acceptable salt thereof; or use of said compound of Formula (1) to prepare a medicament for treating an inflammatory and/or immunological disease or disorder in an animal.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: October 3, 2023
    Assignee: Zoetis Services LLC
    Inventors: Mark R. Cox, Timothy L. Stuk, Todd M. Maddux, Richard Andrew Ewin, Paul D. Johnson, Tomasz Respondek, Graham M. Kyne, Rajendran Vairagoundar
  • Patent number: 11753385
    Abstract: Provided is a production method of kakeromycin and a derivative thereof showing an antifungal activity and cytotoxicity and expected as a new antifungal agent or anticancer agent, by chemical synthesis. A production method of a compound represented by the formula (1): wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; and n is 0 or 1, or a salt thereof, including a step of subjecting a compound represented by the formula (2): wherein R and n are as defined above, or a salt thereof, to an oxidation reaction.
    Type: Grant
    Filed: October 6, 2021
    Date of Patent: September 12, 2023
    Assignees: OP BIO FACTORY CO., LTD., SEED RESEARCH INSTITUTE CO., LTD.
    Inventors: Teruhiko Ishikawa, Morita Iwami
  • Patent number: 11666559
    Abstract: The present disclosure relates to a new class of antimicrobial agents. In particular, this disclosure provides the identification and characterization of novel spiro-lactam compounds as anti-HIV/AIDS and anti-malarial agents. Furthermore, this disclosure also provides the preparation of spiro-?-penicillanic acids, which proved to be potent inhibitors of HIV.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: June 6, 2023
    Assignees: UNIVERSIDADE DE COIMBRA, EGAS MONIZ—COOPERATIVA DE ENSINO SUPERIOR, CRL, INSTITUTO DE MEDICINA MOLECULAR
    Inventors: Teresa Margarida Vasconcelos Dias De Pinho E Melo, Bruna C. Suzano Santos, Inês Bártolo, Rui Miguel Prudêncio Pignatelli, Nuno Eduardo Moura Dos Santos Da Costa Taveira
  • Patent number: 11654141
    Abstract: The present invention provides use of berbamine dihydrochloride in preparation of an Ebola virus inhibitor. In the present invention, the primed glycoprotein of the Ebola virus (EBOV-GPcl) is taken as a target site, and an antiviral active compound with the capability of binding to the EBOV-GPcl, i.e., berbamine dihydrochloride, is obtained through structure-based virtual screening. Berbamine dihydrochloride can specifically inhibit the entry of an Ebola recombinant virus by binding to the target protein EBOV-GPcl, thereby achieving the effect of anti-Ebola virus infection. The half-maximum effect concentration (EC50) of berbamine dihydrochloride against EBOV is 0.49 ?M, which indicates that berbamine dihydrochloride has a strong inhibition effect on EBOV.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: May 23, 2023
    Assignee: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
    Inventors: Shan Cen, Quanjie Li, Dongrong Yi, Yi Shi, Han Wang, Jinming Zhou
  • Patent number: 11655235
    Abstract: The present technology provides pyrrolidine and piperidine compounds or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. In particular, said compounds may be usefully applied in the treatment and prevention of FAP-mediated diseases.
    Type: Grant
    Filed: November 5, 2020
    Date of Patent: May 23, 2023
    Assignee: YUHAN CORPORATION
    Inventors: Tae Han Dong, Yoo Hoi Park, Tae Kyun Kim, Jae Eun Joo, Eun Hye Jung, Jae Won Jeong, Hyun Seung Lee, Do Hoon Kim, Ji Eun Yang, Jun Chui Park, Sang Myoun Lim, Na Ry Ha, Da In Chung, Ji Yeong Gal